Internal Medicine, Endocrinology, Diabetes, & Metabolism · Calhoun, GA
NPI
1275078818
Since 2017
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
815 Curtis Pkwy SE
Calhoun, GA, 30701
Phone (706) 879-5820
Groups this clinician bills Medicare through
Medicare paid, 2024
$73K
2,647 services
Medicare patients, 2024
242
Average age 70
Drug cost, 2024
$1.7M
3,544 prescriptions
Company payments, 2025
$581
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Swati Chopra was code 99214 (office e&m - established), 369 times for 186 patients. In total Swati Chopra billed 2,647 services in 21 codes, and Medicare paid $73K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-08-06.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 369 | 186 | $85.27 | $31K |
| 83036 Blood Count | Office | 197 | 118 | $9.30 | $1,832 |
| 95251 Test - Miscellaneous | Office | 146 | 72 | $24.13 | $3,523 |
| 36415 Venipuncture Blood Collection | Office | 136 | 87 | $8.23 | $1,120 |
| 99204 Office E&M - New | Office | 88 | 88 | $109.08 | $9,599 |
| 96372 Injection Administration | Office | 36 | 12 | $10.51 | $378 |
By year: 2022 $25K for 493 services; 2023 $36K for 727 services; 2024 $73K for 2,647 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 197 | 118 | $9.30 | $1,832 |
| 36415 Venipuncture Blood Collection | 136 | 87 | $8.23 | $1,120 |
Medicare prescription drug claims, 2024
In 2024, the drug Swati Chopra prescribed most often to Medicare patients was Ozempic (Semaglutide), with 348 prescriptions and refills. In total Swati Chopra wrote 3,544 Medicare prescriptions that cost $1.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 348 | 406 | 71 | $373K |
| Levothyroxine Sodium Generic | 227 | 486 | 67 | $1,806 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 165 | 271 | 51 | $26K |
| Jardiance Empagliflozin | 156 | 264 | 40 | $155K |
| Metformin Hcl Generic | 150 | 325 | 44 | $808 |
| Mounjaro Tirzepatide | 141 | 163 | 30 | $171K |
| Metformin Hcl Er Metformin Hcl | 126 | 295 | 38 | $1,016 |
| Tresiba Flextouch U-200 Insulin Degludec | 115 | 195 | 37 | $100K |
| Novolog Flexpen Insulin Aspart | 111 | 196 | 44 | $29K |
| Synthroid Levothyroxine Sodium | 96 | 143 | 20 | $5,714 |
| Pioglitazone Hcl Generic | 95 | 212 | 31 | $970 |
| Glipizide Er Glipizide | 88 | 220 | 30 | $980 |
| Atorvastatin Calcium Generic | 79 | 195 | 23 | $349 |
| Ultra-Fine Short Pen Needle Pen Needle, Diabetic | 76 | 126 | 24 | $6,681 |
| Methimazole Generic | 70 | 146 | 21 | $421 |
Brand drugs: 2,037 claims; generic drugs: 1,168 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Swati Chopra $581 ($581 in general payments such as food, travel and fees) from 12 companies. The largest payer was Boehringer Ingelheim Pharmaceuticals, Inc. with $78.62.
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $78.62 |
| Tandem Diabetes Care, Inc. TNDM | 3 | $76.68 |
| Lilly USA, LLC LLY | 4 | $68.51 |
| CeQur Corporation | 1 | $67.84 |
| Insulet Corporation PODD | 3 | $60.89 |
| Xeris Pharmaceuticals, Inc. | 3 | $53.13 |
| Sequel Med Tech, LLC | 2 | $38.76 |
| Exact Sciences Corporation EXAS | 2 | $36.01 |
| Amgen Inc. AMGN | 2 | $30.87 |
| Sanofi-Aventis U.S. LLC SNY | 1 | $30.3 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.